Disease · MONDO_0015909
Trials147
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.
1 to 20 of 147
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | Phase 2/3 | 361 | 2021-08-13 | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific | BUSULFAN, CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, FLUDARABINE PHOSPHATE, MELPHALAN, THIOTEPA | Its record names the disease | ClinicalTrials.gov |
| NCT00003838 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | Phase 2 | 202 | 2022-10-07 | Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | CYCLOSPORINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT00580034 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | Phase 2 | 176 | 2014-06-03 | Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors | ALEMTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01010217 | Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide | Phase 2 | 176 | 2020-01-07 | Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies | CYCLOPHOSPHAMIDE, FILGRASTIM, FLUDARABINE, MELPHALAN, MESNA, MYCOPHENOLATE MOFETIL, RITUXIMAB, TACROLIMUS ANHYDROUS, THIOTEPA | Its record names the disease | ClinicalTrials.gov |
| NCT00260689 | Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia | Phase 2 | 136 | 2017-06-08 | Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia | ALEMTUZUMAB, ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE), CYCLOSPORINE | Its record names the disease | ClinicalTrials.gov |
| NCT00631163 | Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis | Phase 2 | 102 | 2021-06-29 | Chronic Anemia, Transfusional Hemosiderosis | DEFERASIROX | Its record names the disease | ClinicalTrials.gov |
| NCT00001962 | A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure | Phase 2 | 100 | 2015-05-14 | Aplastic Anemia, Pure Red Cell Aplasia, Diamond Blackfan Anemia | DACLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00326417 | Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) | Phase 1/2 | 97 | 2016-10-04 | Anemia, Aplastic | CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00582933 | Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor | Phase 2 | 96 | 2016-02-01 | Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Allogeneic Marrow Transplant | BUSULFAN, FLUDARABINE, MELPHALAN | Its record names the disease | ClinicalTrials.gov |
| NCT04304820 | Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) | Phase 2 | 80 | 2026-01-09 | Severe Aplastic Anemia | CYCLOSPORINE, ELTROMBOPAG | Its record names the disease | ClinicalTrials.gov |
| NCT02162420 | Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia | Not applicable | 61 | 2025-05-08 | Dyskeratosis Congenita, Aplastic Anemia | ALEMTUZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov |
| NCT00065260 | Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia | Phase 2 | 54 | 2016-03-03 | Aplastic Anemia | ALEMTUZUMAB, ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Its record names the disease | ClinicalTrials.gov |
| NCT02998645 | Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia | Phase 2 | 54 | 2023-12-11 | Severe Aplastic Anemia | CYCLOSPORINE, ELTROMBOPAG | Its record names the disease | ClinicalTrials.gov |
| NCT00806598 | Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome | Phase 2 | 53 | 2013-03-06 | Myelodysplastic Syndrome, Aplastic Anemia | CYCLOSPORINE, METHYLPREDNISOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT00195624 | Alemtuzumab to Treat Severe Aplastic Anemia | Phase 2 | 47 | 2019-08-02 | Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia, Relapse | ALEMTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00922883 | A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients | Phase 2 | 43 | 2018-07-16 | Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia | ELTROMBOPAG | Its record names the disease | ClinicalTrials.gov |
| NCT00053989 | NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders | Phase 2 | 41 | 2020-02-10 | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Fanconi Anemia, Aplastic Anemia | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, METHOTREXATE, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, SARGRAMOSTIM, TACROLIMUS ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT01891994 | Extended Dosing With Eltrombopag for Severe Aplastic Anemia | Phase 2 | 40 | 2018-12-04 | Severe Aplastic Anemia (SAA) | ELTROMBOPAG | Its record names the disease | ClinicalTrials.gov |
| NCT00455312 | Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA | Phase 2/3 | 36 | 2017-05-31 | Dyskeratosis Congenita, Aplastic Anemia | ALEMTUZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, METHYLPREDNISOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT04328727 | Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia | Phase 2 | 36 | 2025-07-17 | Severe Aplastic Anemia (SAA) | CYCLOSPORINE, ELTROMBOPAG | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015909/trials